An official website of the United States government
SNV4818 in Participants With Advanced Solid Tumors
Trial Status: active
This study is testing a new medicine, SNV4818, for people with advanced cancers. The
researchers want to find out if SNV4818 is safe, well-tolerated, and effective in
treating solid tumors. They are investigating different doses in order to find the safest
and most effective one.
Inclusion Criteria
Advanced or metastatic solid tumor with an activating PIK3CA mutation.
Refractory to or intolerant of available therapies
Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
Diagnosis of a primary CNS malignancy
Active brain metastases or carcinomatous meningitis
Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
Inadequate organ function
Clinically significant ECG abnormalities, including QTcF ≥ 470 ms
Additional locations may be listed on ClinicalTrials.gov for NCT06736704.
